Symbiotec Pharmalab Closes Trading Window for Q1 FY27 Results
Symbiotec Pharmalab Limited has closed its trading window from September 01, 2026, until 48 hours after the declaration of Q1 FY27 unaudited financial results. The board meeting date to approve these results will be announced later.
This is a standard procedural announcement related to insider trading regulations and does not directly impact the company's operations or financial performance.
The announcement is a routine regulatory disclosure regarding the closure of the trading window and does not contain any specific financial or operational updates.
Symbiotec Pharmalab Limited has announced the closure of its trading window for dealing in the company's securities. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders.
The trading window will be shut for all Designated Persons and their immediate relatives starting from Tuesday, September 01, 2026. It will remain closed until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026.
The company will inform the stock exchanges in due course about the date of the Board of Directors' meeting, which will be convened to consider and approve the aforementioned unaudited financial results.
A plain-language summary of a public exchange filing by Symbiotec Pharmalab Limited. Read the original for the full detail.